Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease).

Current pharmaceutical design - 1 Jan 2020

Kubaski Francyne, Vairo Filippo, Baldo Guilherme, de Oliveira Poswar Fabiano, Corte Amauri Dalla, Giugliani Roberto

Abstract excerpt

BACKGROUND: Mucopolysaccharidosis type II (Hunter syndrome, or MPS II) is an X-linked lysosomal disorder caused by the deficiency of iduronate-2-sulfatase, which leads to the accumulation of glycosaminoglycans (GAGs) in a variety of tissues, resulting in a multisystemic disease that can also impair the central nervous system (CNS). OBJECTIVE: This review focuses on providing the latest information and expert...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Replacement Therapy
Share to Glycosaminoglycans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iduronate Sulfatase

Share to Mucopolysaccharidosis II

Share to Phenotype

Source

Identifiers

PMID: 33138761
DOI: 10.2174/1381612826666200724161504

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease).PMID 33138761Read ↗

Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?Semantic proximity Read ↗

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.Semantic proximity Read ↗

Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and BeyondSemantic proximity Read ↗

Phase I and II clinical trials for the mucopolysaccharidosesSemantic proximity Read ↗

Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment.Semantic proximity Read ↗

Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatmentSemantic proximity Read ↗

A Review Of The Clinical Outcomes In Idursulfase-Treated And Untreated Filipino Patients With Mucopolysaccharidosis Type II: Data From The Local Lysosomal Storage Disease RegistrySemantic proximity Read ↗

Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.Semantic proximity Read ↗

Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System–Directed, AAV9-Mediated Iduronate Sulfatase Gene TransferSemantic proximity Read ↗

Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare diseaseSemantic proximity Read ↗

Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome.Semantic proximity Read ↗

Mucopolysaccharidosis III: Molecular basis and treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.